BeOne Medicines AG
ONC
$335.17
$2.460.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.02B | 4.61B | 4.23B | 3.86B | 3.32B |
| Total Other Revenue | 17.27M | 8.15M | 8.15M | 8.15M | 8.15M |
| Total Revenue | 5.03B | 4.62B | 4.24B | 3.87B | 3.33B |
| Cost of Revenue | 699.14M | 673.09M | 646.62M | 606.55M | 545.45M |
| Gross Profit | 4.33B | 3.95B | 3.59B | 3.26B | 2.78B |
| SG&A Expenses | 2.06B | 1.98B | 1.89B | 1.86B | 1.73B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.26M | -1.26M | -1.26M | -1.26M | 23.87M |
| Total Operating Expenses | 4.85B | 4.72B | 4.53B | 4.43B | 4.20B |
| Operating Income | 187.09M | -96.29M | -291.34M | -563.79M | -870.22M |
| Income Before Tax | 201.98M | -43.49M | -248.96M | -513.28M | -768.14M |
| Income Tax Expenses | 121.25M | 121.97M | 131.22M | 119.32M | 59.56M |
| Earnings from Continuing Operations | 80.73 | -165.46 | -380.18 | -632.60 | -827.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.73M | -165.46M | -380.18M | -632.60M | -827.70M |
| EBIT | 187.09M | -96.29M | -291.34M | -563.79M | -870.22M |
| EBITDA | 326.09M | 77.07M | -124.09M | -404.06M | -729.55M |
| EPS Basic | 9.11 | -20.51 | -46.78 | -78.25 | -102.98 |
| Normalized Basic EPS | 1.26 | -0.23 | -1.46 | -3.06 | -6.79 |
| EPS Diluted | 6.72 | -22.01 | -47.36 | -79.62 | -104.35 |
| Normalized Diluted EPS | 1.20 | -0.26 | -1.46 | -3.06 | -6.79 |
| Average Basic Shares Outstanding | 431.72M | 427.41M | 423.79M | 421.14M | 418.95M |
| Average Diluted Shares Outstanding | 34.19M | 33.53M | 32.93M | 32.39M | 32.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -8.76% | -3.81% | -2.29% | -1.75% |